About atricure inc. - ATRC
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.
ATRC At a Glance
AtriCure, Inc.
7555 Innovation Way
Mason, Ohio 45040
| Phone | 1-513-755-4100 | Revenue | 465.31M | |
| Industry | Medical Specialties | Net Income | -44,698,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 16.547% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,300 | |
| View SEC Filings |
ATRC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.085 |
| Price to Book Ratio | 3.24 |
| Price to Cash Flow Ratio | 128.90 |
| Enterprise Value to EBITDA | -149.683 |
| Enterprise Value to Sales | 2.985 |
| Total Debt to Enterprise Value | 0.055 |
ATRC Efficiency
| Revenue/Employee | 357,928.462 |
| Income Per Employee | -34,383.077 |
| Receivables Turnover | 7.712 |
| Total Asset Turnover | 0.761 |
ATRC Liquidity
| Current Ratio | 3.648 |
| Quick Ratio | 2.622 |
| Cash Ratio | 1.671 |
ATRC Profitability
| Gross Margin | 74.038 |
| Operating Margin | -6.02 |
| Pretax Margin | -9.386 |
| Net Margin | -9.606 |
| Return on Assets | -7.308 |
| Return on Equity | -9.642 |
| Return on Total Capital | -8.316 |
| Return on Invested Capital | -8.333 |
ATRC Capital Structure
| Total Debt to Total Equity | 16.602 |
| Total Debt to Total Capital | 14.238 |
| Total Debt to Total Assets | 12.56 |
| Long-Term Debt to Equity | 15.993 |
| Long-Term Debt to Total Capital | 13.716 |